Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Conversion of Preferred Shares	Conversion of Warrants	Total LianBio Shareholders’ Equity (Deficit)	Total LianBio Shareholders’ Equity (Deficit) Conversion of Preferred Shares	Total LianBio Shareholders’ Equity (Deficit) Conversion of Warrants	Ordinary Shares	Ordinary Shares Conversion of Preferred Shares	Ordinary Shares Conversion of Warrants	Treasury Shares	Additional Paid in Capital	Additional Paid in Capital Conversion of Preferred Shares	Additional Paid in Capital Conversion of Warrants	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Non- Controlling Interest	Non- Controlling Interest Conversion of Warrants
Beginning balance (in shares) at Dec. 31, 2020	10,971,231
Beginning balance at Dec. 31, 2020	$ 349,789
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series A Preferred Shares, net of issuance costs (in shares)	52,947
Issuance of Series A Preferred Shares, net of issuance costs (in shares)	$ 2,940
Conversion of preferred shares into ordinary shares upon initial public offering	(11,024,178)
Conversion of preferred shares into ordinary shares upon initial public offering	$ (352,729)
Ending balance (in shares) at Dec. 31, 2021	0
Ending balance at Dec. 31, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020							20,477,338
Beginning balance (in shares) at Dec. 31, 2020										0
Beginning balance at Dec. 31, 2020	(98,070)			$ (132,843)			$ 0			$ 0	$ 31,132			$ (40)	$ (163,935)	$ 34,773
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	8,664			8,664							8,664
Conversion of convertible securities into ordinary shares (in shares)								64,467,176	78,373
Conversion of convertible securities into ordinary shares		$ 352,730	$ 0		$ 352,730	$ 10,414		$ 2				$ 352,728	$ 10,414				$ (10,414)
Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares)							20,906,116
Issuance of ordinary shares upon initial public offering, net of issuance costs	304,785			304,785							304,785
Conversion of Warrants issued in license agreement into LianBio ordinary shares and LianBio warrants	9,415															9,415
Exercise of options (in shares)							1,346,455
Exercise of options	5,546			5,546							5,546
Net Loss	(196,300)			(196,300)											(196,300)
Comprehensive income (loss)	$ 566			566										566
Ending balance (in shares) at Dec. 31, 2021	107,275,458						107,275,458
Ending balance (in shares) at Dec. 31, 2021										0
Ending balance at Dec. 31, 2021	$ 387,336			353,562			$ 2			$ 0	713,269			526	(360,235)	33,774
Ending balance (in shares) at Dec. 31, 2022	0
Ending balance at Dec. 31, 2022	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	19,148			19,148							19,148
Redemption of ordinary shares pursuant to non-recourse secured promissory note (in shares)										1,309,907
Retirement of treasury shares (in shares)							(1,309,907)			(1,309,907)
Retirement of treasury shares	$ (1,651)			(1,651)							(1,651)
Conversion of convertible securities into ordinary shares (in shares)									78,373
Exercise of options (in shares)	1,000,000						1,000,000
Exercise of options	$ 1,710			1,710							1,710
Net Loss	(110,290)			(110,290)											(110,290)
Comprehensive income (loss)	$ (2,606)			(2,606)										(2,606)
Ending balance (in shares) at Dec. 31, 2022	107,043,924						107,043,924
Ending balance (in shares) at Dec. 31, 2022										0
Ending balance at Dec. 31, 2022	$ 293,647			$ 259,873			$ 2			$ 0	$ 732,476			$ (2,080)	$ (470,525)	$ 33,774